This bioactivity is of high relevance, because NF-κB is a key regulator of inflammation, and the pro-inflammatory NF-κB activation contributes to the pathogenesis of diabetes, which overall might suggest that anti-inflammatory effects of amorfrutins may potentially be also implied in their antidiabetic action. Here, NFKB1 is linked to diabetes mellitus.